Gyre Therapeutics Inc. (GYRE) - Total Liabilities
Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) has total liabilities worth $25.03 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gyre Therapeutics Inc. - Total Liabilities Trend (2002–2025)
This chart illustrates how Gyre Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Gyre Therapeutics Inc. (GYRE) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Gyre Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Gyre Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yes Optoelectronics Co Ltd Class A
SHE:002952
|
China | CN¥259.78 Million |
|
Dexus Convenience Retail REIT
AU:DXC
|
Australia | AU$248.27 Million |
|
SmartFinancial, Inc.
NASDAQ:SMBK
|
USA | $5.25 Billion |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
China | CN¥247.79 Million |
|
HelloFresh SE
XETRA:HFG
|
Germany | €1.58 Billion |
|
Chularat Hospital Public Company Limited
BK:CHG-R
|
Thailand | ฿2.21 Billion |
|
Musti Group Oyj
HE:MUSTI
|
Finland | €288.33 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Gyre Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gyre Therapeutics Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gyre Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gyre Therapeutics Inc. (2002–2025)
The table below shows the annual total liabilities of Gyre Therapeutics Inc. from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $23.85 Million | -11.68% |
| 2024-12-31 | $27.00 Million | -73.68% |
| 2023-12-31 | $102.59 Million | +718.36% |
| 2022-12-31 | $12.54 Million | -13.98% |
| 2021-12-31 | $14.57 Million | -22.39% |
| 2020-12-31 | $18.78 Million | -37.86% |
| 2019-12-31 | $30.22 Million | +507.40% |
| 2018-12-31 | $4.97 Million | -43.07% |
| 2017-12-31 | $8.74 Million | -60.31% |
| 2016-12-31 | $22.02 Million | -42.20% |
| 2015-12-31 | $38.10 Million | +1207.34% |
| 2014-12-31 | $2.91 Million | -74.13% |
| 2013-12-31 | $11.26 Million | -17.58% |
| 2012-12-31 | $13.66 Million | -83.70% |
| 2011-12-31 | $83.84 Million | -50.95% |
| 2010-12-31 | $170.94 Million | -31.73% |
| 2009-12-31 | $250.39 Million | +508.06% |
| 2008-12-31 | $41.18 Million | -13.09% |
| 2007-12-31 | $47.38 Million | +189.44% |
| 2006-12-31 | $16.37 Million | -91.41% |
| 2005-12-31 | $190.48 Million | +5.14% |
| 2004-12-31 | $181.17 Million | +12291.91% |
| 2003-12-31 | $1.46 Million | -29.98% |
| 2002-12-31 | $2.09 Million | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more